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Abstract
Background: The circumferential resection margin (CRM) is a significant prognostic factor for local recurrence, distant metastasis, and 
survival after rectal cancer surgery. Therefore, availability of this parameter is essential. Although the Dutch total mesorectal excision 
trial raised awareness about CRM in the late 1990s, quality assurance on pathologic reporting was not available until the Dutch Surgical 
Colorectal Audit (DSCA) started in 2009. The present study describes the rates of CRM reporting and involvement since the start of the DSCA 
and analyzes whether improvement of these parameters can be attributed to the audit. Methods: Data from the DSCA (2009–2013) were 
analyzed. Reporting of CRM and CRM involvement was plotted for successive years, and variations of these parameters were analyzed in a 
funnelplot. Predictors of CRM involvement were determined in univariable analysis and the independent influence of year of registration 
on CRM involvement was analyzed in multivariable analysis. Results: A total of 12,669 patients were included for analysis. The mean per-
centage of patients with a reported CRM increased from 52.7% to 94.2% (2009–2013) and interhospital variation decreased. The percent-
age of patients with CRM involvement decreased from 14.2% to 5.6%. In multivariable analysis, the year of DSCA registration remained 
a significant predictor of CRM involvement. Conclusions: After the introduction of the DSCA, a dramatic improvement in CRM reporting 
and a major decrease of CRM involvement after rectal cancer surgery have occurred. This study suggests that a national quality assurance 
program has been the driving force behind these achievements. (J Natl Compr Canc Netw 2015;13:1111–1119)
the inked resection margin. This is the most significant 
prognostic factor for local recurrence, distant metastasis, 
and survival after rectal cancer surgery.4 Therefore this 
parameter provides important information on both the 
quality of surgical resection and the prognosis of the pa-
tient. 
Because of its prognostic value, the CRM has been 
frequently used as a surrogate end point in randomized 
controlled trials.5,6 In The Netherlands, a standard pa-
thology protocol to examine a TME specimen was in-
troduced in the 1990s, related to the start of the Dutch 
TME trial.5 Because of this standardization, 97% of pa-
tients included in this trial had a reported CRM.2 In 
subsequent years, until the start of the Dutch Surgical 
Colorectal Audit (DSCA) in 2009, there was no na-
tional quality assurance on histopathologic reporting, 
and the CRM was presumably less frequently reported 
in routine practice outside a trial setting.  
The DSCA evaluates and reports on the quality of 
care of primary colorectal cancer surgery.7 It provides pe-
riodic feedback to all hospitals in The Netherlands on a 
set of quality measures, including 2 indicators regarding 
the CRM in rectal cancer surgery. The objective of this 
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Background
Surgical resection remains the cornerstone of cura-
tive treatment in rectal cancer.1 The implementation 
and standardization of the total mesorectal excision 
(TME) technique and the introduction of preopera-
tive (chemo)radiotherapy have led to improved onco-
logic outcomes.2,3 The circumferential resection margin 
(CRM) indicates the distance from the tumor to the re-
section plane in a transverse section through the TME 
specimen. Tumor-negative noninvolved CRM is defined 
as the absence of microscopic tumor cells within 1 mm of 
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Statistical Analyses
Differences in baseline characteristics between dif-
ferent years of the study period were analyzed using a 
chi-square test. A P value of less than .05 was consid-
ered statistically significant. Potential predictors of 
CRM involvement were determined in a univariable 
analysis. Variables with a significance level of P less 
than .10 in univariable analysis were subsequently 
included in a multivariable logistic regression model 
as categorical variables. To analyze the possible ef-
fect of the DSCA on CRM involvement, the year of 
DSCA registration was added as an ordinal variable 
to the multivariable model. A scatterplot with each 
dot representing an individual hospital was used to 
visualize the hospital variation in CRM reporting for 
the years 2009, 2011, and 2013. The number of pa-
tients who underwent a resection for rectal cancer is 
plotted on the x axis and the percentage of patients 
with a reported CRM on the y axis. The overall 
mean percentage is represented as a horizontal line. 
A funnel plot was used to visualize the hospital 
variation in case-mix–corrected CRM involvement 
for the years 2009, 2011, and 2013. Variables includ-
ed in this case-mix correction for CRM involvement 
included type of resection, laparoscopic resection, 
emergency surgery, and pathologic T classification. 
The number of patients with a reported CRM is plot-
ted on the x axis and the percentage of CRM in-
volvement on the y axis. The overall average CRM 
involvement is represented by a horizontal line with 
its 95% and 99% confidence limits, based on a Pois-
son distribution, varying in relation to the popu-
lation size of each hospital. To evaluate the linear 
effect of year of registration on CRM involvement, 
we performed a linear-by-linear association test. Sta-
tistical analyzes were performed in PASW Statistics, 
version 20 (SPSS Inc., Chicago, IL). 
Results
Patient and Treatment Characteristics
A total of 12,178 patients, registered by 91 hospi-
tals, were included for analysis. Patient, tumor, and 
treatment characteristics are displayed in Table 1. 
A decrease occurred in unspecified clinical T clas-
sification (P<.001). The use of MRI as preoperative 
imaging technique increased (P<.001) and so did 
the percentage of patients who were preoperatively 
discussed in a multidisciplinary team (MDT) meet-
study was to evaluate the rates of CRM reporting and 
involvement throughout the successive years of the 
DSCA registration. Secondly, it analyzes changes in 
these CRM-related quality indicators over time and 
investigates the potential contribution of the DSCA 
to observe changes in a multivariable model. 
Methods 
Data were derived from the DSCA, a disease-specific 
national audit. This audit collects information on 
patient, tumor, treatment, and outcome character-
istics and contains data on approximately 97% of 
all patients who underwent a resection for primary 
colorectal carcinoma in The Netherlands.8 The data 
set is based on evidence-based guidelines and com-
pared on a yearly basis with the data registered in the 
Netherlands Cancer Registry (NCR). Details of this 
data set regarding data collection and methodology 
have been published previously.7,9 
Patients
For this study, no ethical approval or informed con-
sent was required under Dutch law. All patients 
(N=13,029) undergoing surgical resection for pri-
mary rectal cancer between January 1, 2009, and 
December 31, 2013, and registered in the DSCA be-
fore March 15, 2014, were evaluated. Patients with 
multiple synchronous tumors with at least 1 tumor 
located in the rectum were included. Patients who 
underwent a local excision with or without comple-
tion TME surgery were excluded (n=241). Patients 
with a complete pathologic response (ypT0) on neo-
adjuvant (chemo)radiotherapy were also excluded 
(n=610). Minimal data requirements to consider a 
patient eligible for analyzes were information on tu-
mor location and date of surgery. Baseline character-
istics of the study population and treatment charac-
teristics are displayed per year in Table 1. 
Circumferential Resection Margin
The mean percentage of reported CRM and the re-
ported CRM rate per hospital for each year of the study 
period were calculated. The CRM was considered posi-
tive if tumor cells were present within 1 mm from the 
inked margin according to the definition of the Dutch 
guideline.10 CRM involvement was only calculated for 
patients with a reported CRM. The mean percentage 
of CRM involvement and the percentage of CRM in-
volvement per hospital were calculated for each year.  
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Table 1   Baseline Characteristics of Patients Who Underwent Rectal Cancer Resection  
Registered in the DSCA, 2009–2013
  2009 2010 2011 2012 2013
χ2  
P Value
Male 61.5% 62.2% 63.7% 61.1% 63.1% .291
Age, y           .311
 75+ 28.9% 27.0% 28.2% 28.1% 29.6%  
ASA score           .884
 III 16.9% 16.8% 17.6% 17.8% 17.3%  
BMI, kg/m2           .005
 30+ 13.5% 16.6% 15.2% 17.9% 16.0%  
Clinical T classification           <.001
 cT1 3.5% 3.8% 3.8% 2.7% 2.3%  
 cT2 19.2% 23.3% 23.3% 24.0% 21.2%  
 cT3 47.0% 46.6% 52.1% 55.7% 61.9%  
 cT4 9.9% 8.7% 7.9% 8.6% 9.1%  
 cTx/unknown 20.4% 17.5% 12.9% 8.9% 5.5%  
Distance from tumor to anus           <.001
 ≤5 cm 35.8% 32.3% 34.9% 33.3% 36.2%  
 6–10 cm 35.6% 39.0% 38.5% 38.9% 39.0%  
 >10 cm 20.1% 20.9% 20.3% 23.0% 21.1%  
 Unknown 8.5% 7.8% 6.2% 4.8% 3.7%  
MRI           <.001
 Yes 78.4% 83.7% 88.0% 90.2% 91.9%  
 Unknown 11.3% 6.7% 3.2% 1.7% 1.8%  
MDT           <.001
 Yes 79.0% 90.4% 95.9% 98.1% 98.7%  
Neoadjuvant therapy           <.001
 None 21.3% 16.9% 14.1% 18.2% 18.6%  
 SCRT 41.9% 45.4% 45.7% 39.2% 35.9%  
 SCRT-ds 3.5% 3.7% 4.4% 6.3% 8.8%  
 CRT 33.0% 33.9% 35.5% 36.3% 36.5%  
 Other 0.3% 0.1% 0.3% 0.0% 0.2%  
Procedure           <.001
 LAR 58.0% 61.5% 65.8% 70.5% 68.9%  
 APR 31.6% 29.4% 29.4% 26.6% 28.6%  
 Other/nonspecified 10.4% 9.2% 4.8% 2.8% 2.6%  
Approach           <.001
 Laparoscopic 33.2% 36.2% 43.2% 54.7% 65.5%  
Setting           <.001
 Nonelective 5.4% 2.6% 1.7% 2.3% 1.5%  
Pathologic T classification           <.001
 (y)pT1 7.4% 7.1% 8.3% 8.5% 8.8%  
 (y)pT2 28.5% 32.0% 33.9% 32.8% 33.3%  
 (y)pT3 46.8% 47.7% 49.1% 51.9% 51.9%  
 (y)pT4 6.6% 5.8% 5.2% 4.9% 4.6%  
 (y)pTX/unknown 10.6% 7.3% 3.5% 2.0% 1.5%  
Pathologic N classification           <.001
 pN0 58.7% 61.5% 61.0% 62.6% 63.0%  
 pN1 20.2% 23.8% 25.8% 23.8% 24.5%  
 pN2 12.8% 11.6% 10.4% 12.6% 11.8%  
 pNx/unknown 8.3% 3.0% 2.7% 1.1% 0.8%  
Metastatic disease 8.3% 7.8% 7.5% 8.2% 7.5% .806
Abbreviations: APR, abdominoperineal resection; ASA, Association of Anesthesiologists; BMI, body mass index; CRM, circumferential resection 
margin; CRT, chemoradiotherapy; DSCA, Dutch Surgical Colorectal Audit; MDT, multidisciplinary team meeting; SCRT, short-course radiotherapy; 
SCRT-ds, short-course radiotherapy, delayed surgery; LAR, low anterior resection.
ing (P<.001). A peak incidence occurred in the 
use of neoadjuvant therapy in 2011, and was still 
greater than 80% in 2013. An increase was seen in 
the use of short-course radiotherapy with delayed 
(>3 weeks) surgery (SCRT-ds) and chemoradio-
therapy (CRT), both with a potential downsizing 
effect. The use of laparoscopic surgery doubled dur-
ing this 5-year period; from 33% in 2009 to 66% in 
Year of DSCA Registration
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2009
2011
2013
Figure 1  Scatterplots showing the mean percentage and hospital varia-
tion of patients with a reported circumferential resection margin (CRM) 
in (A) 2009, (B) 2011, and (C) 2013.
2013 (P<.001). Nonelective resections decreased 
to 1.5% (P<.001). 
Reporting of CRM
Figure 1 shows the mean percentage of patients with 
a reported CRM per year and displays the variation 
on this parameter between hospitals in 2009, 2011, 
and 2013. In 2009, the mean reported CRM rate was 
52.7%, which varied from 0% to 100% between in-
dividual hospitals. The mean percentage of patients 
with a reported CRM increased to 94.2% in 2013 
and interhospital variation decreased (range, 33%–
100% in 2013). Baseline characteristics between pa-
tients with a reported and unreported CRM are dis-
played in Table 2, which shows that the percentage 
of patients without a reported T and N classification 
was higher among patients without a reported CRM 
than among patients with a reported CRM. 
CRM Involvement
In 2009, the mean rate of CRM involvement was 
14.2% in patients with a reported CRM (Table 3). In 
2013, the mean percentage of CRM involvement was 
5.6% in the 94% of patients with a reported CRM. Fig-
ure 2 shows the variation of CRM involvement among 
the Dutch hospitals in 2009, 2011, and 2013. The 
mean percentage of patients with an involved CRM 
was significantly lower in 2013 compared with 2009 
(P<.001). Furthermore, interhospital variation had de-
creased since the start of the DSCA (range, 0%–90% 
in 2009; range, 0%–22% in 2013). None of the hospi-
tals were a negative outlier; however, because of low 
annual numbers of rectal cancer resections per hospital 
per year, confidence intervals are wide. Year of DSCA 
registration had a significant effect on CRM involve-
ment in the linear-by-linear association test (P=.005).
Predictors of CRM Involvement
Table 4 displays the univariable and multivariable 
analysis of potential predictors for CRM involve-
ment, including the year of DSCA registration. In 
multivariable analysis, the year of DSCA registra-
tion remained a significant influence on CRM in-
volvement, with an odds ratio of 0.47 for registra-
tion year 2013 compared with 2009. Together with 
the year of DSCA registration, clinical T classifica-
tion, procedure, approach, setting, and pathologic 
T classification had a significant influence on CRM 
involvement. To consider the correlation in the 
multivariate model between clinical and pathologic 
T classification, we repeated the multivariable analy-
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tients with a reported CRM in rectal cancer surgery. 
Alongside this improvement, there has been a major 
decrease of CRM involvement, which is known to 
have a significant effect on the long-term outcomes 
of patients with rectal cancer. Such substantial prog-
ress in the quality of rectal cancer care has not been 
observed since the introduction and standardization 
of the TME technique and the concomitant use of 
neoadjuvant therapy.3 Improvement in CRM report-
ing is almost exclusively attributable to the national 
audit, and the present multivariable analysis also sug-
gests that the DSCA was a driving force behind the 
significant increase in tumor-free resection margins. 
Population-based studies and other national au-
dits on rectal cancer confirmed that the CRM, as an 
important measure for the quality of surgical resec-
tion, was often lacking in the pathology report.11–14 
Swellengrebel et al15 performed a population study 
on the value of multidisciplinary team meetings in 
The Netherlands between 2006 and 2008, right be-
fore the start of the DSCA, and showed that only 
61% of patients had a reported CRM. This is sub-
stantially lower than the 97% reported CRM rate in 
the Dutch TME trial (1996–1999), confirming again 
that a trial setting does not represent routine daily 
practice. But why was the standardized pathology re-
porting from the TME trial not implemented in The 
Netherlands? This is especially important to ask giv-
en the numerous publications from The Netherlands 
at that time showing that CRM is one of the most 
important outcome parameters in rectal cancer.4,16–19 
Apparently, confronting the individual hospitals 
with their data, benchmarking their outcomes, and 
making CRM reporting a quality indicator that is 
made available to external parties is what eventually 
does lead to practice changing. The present analysis 
sis without pathologic T classification; results, how-
ever, remained unchanged (data not shown). 
Discussion
After the introduction of the DSCA as a quality as-
surance initiative in The Netherlands, a dramatic 
improvement has occurred in the percentage of pa-
Table 2   Baseline Characteristics of Tumors  
With and Without a Reported CRM
  No Yes
χ2 
P Value
Clinical T classification     <.001
  cT1 5.5% 2.5%  
  cT2 21.2% 22.7%  
  cT3 39.2% 57.0%  
  cT4 7.8% 9.1%  
 cTx/unknown 26.2% 8.7%  
Neoadjuvant therapy     <.001
 None 29.9% 14.2%  
 SCRT 37.9% 42.6%  
 SCRT-ds 2.9% 6.2%  
 CRT 29.0% 36.9%  
 Other 0.3% 0.2%  
Procedure     <.001
 LAR 62.9% 66.0%  
 APR 24.1% 30.4%  
 Other/nonspecified 13.0% 3.6%  
Pathologic T classification   <.001
 (y)pT1 10.2% 7.4%  
 (y)pT2 29.5% 33.0%  
 (y)pT3 38.7% 52.8%  
 (y)pT4 6.8% 5.0%  
 (y)pTX/unknown 14.9% 1.8%  
Pathologic N classification   <.001
 pN0 61.4% 61.5%  
 pN1 21.0% 24.5%  
 pN2 9.4% 12.5%  
 pNx/unknown 8.1% 1.4%  
Metastatic disease 8.1% 7.8% .631
Abbreviations: APR, abdominoperineal resection; CRM, circumferential 
resection margin; CRT, chemoradiotherapy; LAR, low anterior 
resection; SCRT, short-course radiotherapy; SCRT-ds, short-course 
radiotherapy, delayed surgery.
Table 3   Reported CRM and CRM  
Involvement, 2009–2013
Year
Totala
N
 
Reported CRM
 
CRMb
n % n %
2009 2056 1084 52.7 154 14.2
2010 2447 1531 62.6 185 12.1
2011 2462 1956 79.4 177 9.0
2012 2692 2480 92.1 197 7.9
2013 2521 2375 94.2 134 5.6
Abbreviation: CRM, circumferential resection margin. 
aPatients who should have a reported CRM.
Reported CRM
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provement in CRM reporting was found, with still 
more than 30% of patients without a reported CRM 
in 2013. Remarkably similar results as those observed 
in The Netherlands were found by a regional Qual-
ity Initiative in Canada in a population of 1.3 mil-
lion inhabitants for whom colorectal cancer surgery 
is provided in 8 community hospitals and 3 teaching 
hospitals.21 During 2-yearly voluntary workshops, 
quality markers were selected by the participating 
surgeons, together with the commencement of im-
provement interventions, such as auditing and feed-
back, preoperative multidisciplinary consultation, 
and a system event–reporting system. In the period 
between 2006 and 2012, CRM reporting improved 
from 55% to 93% and CRM involvement decreased 
from 14% to 6%. In the limitations of this study, 
the authors question the generalizability of their 
findings. Our study proves that almost identical im-
provements can be achieved by just auditing, even at 
a national level with more than 16 million inhabit-
ants.
This positive effect of feedback on CRM in-
volvement has been described previously. In the 
MRC CR07 trial, quality of the resection speci-
men was prospectively assessed and reported to the 
surgeons. As the study proceeded, the percentage 
of CRM involvement decreased significantly from 
21% to 10%.22 Evaluation of the TME specimen 
and assessment of the CRM by the pathologist pro-
vide direct feedback to the surgeon on the techni-
cal performance of the resection, and therefore they 
should be dedicated team members who participate 
in multidisciplinary meetings in which patients are 
discussed postoperatively.19 Furthermore, Quirke et 
al22 also pointed out the possible influence of the in-
troduction of standard preoperative MDT meetings 
and local staging with MRI, which both could have 
led to the decreased percentage of CRM involve-
ment in the MRC CR07 study. The DSCA included 
preoperative MRI and the discussion of patients in 
a preoperative MDT meeting as quality indicators, 
and improvements in both indicators have been ob-
served (Table 1). Because both preoperative MRI 
and MDT meetings were already an obligatory part 
of the diagnostic pathway for patients with rectal 
cancer according to the Dutch national guidelines, 
the improvements can also be seen as a result of the 
DSCA. Both factors were significantly associated 
with CRM involvement in univariable analysis, but 
2009
2011
2013
Figure 2  Funnelplot showing the case-mix–corrected percentage of 
patients with an involved circumferential resection margin (CRM) per 
hospital in (A) 2009, (B) 2011, and (C) 2013.
shows that quality indicators play an important role 
in identifying quality concerns and variation, and 
enable targeted quality improvement projects.
Other countries with a national audit on rectal 
cancer, such as the United Kingdom, also reported 
on CRM-related quality indicators.20 A decrease in 
CRM involvement has been observed by the Na-
tional Bowel Cancer Audit Programme (NBOCAP) 
in the United Kingdom, although only a minor im-
C
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lost their significance in multivariable analysis. Oth-
er changes during the study period that may have 
contributed to the decrease of CRM involvement 
in our study period are the increased use of down-
staging radiotherapy regimens (SCRT-ds and CRT), 
which indeed were shown to be related to the risk of 
an involved CRM in univariable analysis, but not in 
multivariable analysis. The above-mentioned factors 
Table 4   The Influence of the Year of DSCA Registration on CRM Involvement in a  
Multivariable Analysis
Variable (ref)
Univariate Multivariate
    P Value OR
CI
Lower Upper
Clinical T classification (cT1) <.001      
cT2   1.33 0.67 2.65
cT3   1.21 0.62 2.36
cT4   1.33 0.65 2.68
cTx   0.95 0.47 1.96
Distance from tumor to anus (>10 cm) <.001      
≤5 cm   1.16 0.90 1.51
6–10 cm   0.95 0.76 1.18
Unknown   1.09 0.75 1.59
MRI (no) .06      
 Yes   1.04 0.80 1.35
MDT (no) .055 0.96 0.68 1.36
 Yes        
Downsizing radiotherapy (no) <.001      
 Yes   1.15 0.96 1.37
Procedure (LAR) <.001      
APR   1.49 1.21 1.84
Other/nonspecified   1.49 1.02 2.16
Approach (open) <.001      
Laparoscopic   0.82 0.70 0.97
Setting (elective) <.001      
Urgent   2.22 1.43 3.47
Pathologic T classification ((y)pT1) <.001      
(y)pT2   1.52 0.82 2.81
(y)pT3   6.35 3.54 11.40
(y)pT4   29.19 15.68 54.33
(y)pTx   2.43 1.00 5.90
Year of DSCA registration (2009) <.001      
2010   0.97 0.75 1.25
2011   0.75 0.58 0.96
2012   0.67 0.52 0.86
2013   0.47 0.35 0.61
Abbreviations: APR, abdominoperineal resection; ASA, Association of Anesthesiologists; CRM, circumferential resection margin; DSCA, Dutch 
Surgical Colorectal Audit; LAR, low anterior resection; MDT, multidisciplinary team meeting; OR, odds ratio.
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could also have slightly influenced CRM reporting. 
A multivariate analysis (data not shown), however, 
showed a significant and independent effect of the 
year of registration on CRM reporting, when the ef-
fect was corrected for all these factors. The positive 
impact of increased use of minimally invasive tech-
niques on CRM involvement is difficult to interpret, 
because a meta-analysis of randomized controlled 
trials revealed no difference in CRM involvement 
between laparoscopic and open TME surgery.19 This 
finding could reflect the use of laparoscopic surgery 
by more specialized colorectal surgeons within more 
dedicated teams, but it might also be influenced by 
the inherent risk of selection bias within population 
studies. Although the influence of the approach on 
CRM involvement was analyzed in a multivariate 
model, there could be unmeasured factors that influ-
enced the decision between open and laparoscopic 
resection.
No other important changes in the treatment of 
rectal cancer occurred in The Netherlands during 
the years examined by the present study. The mul-
tivariable analysis demonstrates the independent 
significant influence of the registration year on the 
risk of CRM involvement, which strenghtens the ar-
gument that the DSCA has been one of the leading 
factors in the major improvement of CRM involve-
ment in The Netherlands in only a 5-year period. 
The limitation of this study is that it remains 
difficult to estimate to what extent the audit has in-
fluenced the improved outcome of CRM reporting 
and involvement. Although we think we addressed 
the most important clinical changes, we cannot ex-
clude the possibility of other clinical changes that 
could have influenced these improvements and are 
not captured in the DSCA database. Furthermore we 
cannot exclude some reporting bias. Table 1 shows a 
disproportionate increase of mid-rectal tumors and 
low anterior resection procedures, and some hospi-
tals with low numbers of patients with a reported 
CRM might have reported relatively more patients 
with CRM involvement in the first registration 
years. However, this seems unlikely, because a pop-
ulation-based study from The Netherlands showed 
equal CRM involvement in that period.15 Further-
more, the 14% CRM involvement at the start of the 
DSCA is even favorable if compared with the 16% 
CRM involvement in the Dutch TME trial, especial-
ly considering the fact that the audit also includes 
locally advanced rectal cancer.2  
Conclusions
A marked improvement has occurred in the percent-
age of patients with a reported CRM since the start of 
the DSCA as a national quality assurance program. 
Furthermore, there has been a significant decrease of 
patients with CRM involvement, which contributes 
to a better prognosis for these patients. Few other 
interventions in the care of patients with rectal can-
cer have led to such magnitude of improvements in 
a relatively short period, and this shows the value of 
national auditing as a tool for quality improvement. 
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